[The clinical significance of the lamotrigine pharmacokinetic variability]. / Klinicheskoe znachenie farmakokineticheskoi variabel'nosti lamotridzhina.

AIM: To estimate pharmacokinetic variability of lamotrigine (LTG) and its clinical significance. MATERIAL AND METHODS: One hundred patients, including 74 women, aged from 18 to 77 years (38.23±14.37 years), with focal epilepsy were examined. Monotherapy with LTG was administered to 54 patients, duotherapy to 46 patients (LTG and valproic acid combination to 27 patients, LTG and liver enzymes inducers to 19 patients). Patients underwent procedures of therapeutic drug monitoring (TDM). Minimal (Cssmin) and maximal (Cssmax) steady-state LTG plasma concentrations, and concentration-to-weight ratio (CDR) were calculated. RESULTS AND CONCLUSION: In patients who used LTG in monotherapy, LTG Cssmin was 5.6±4.65 mg/l, Cssmax 7.59±5.54 mg/l. In the group that received LTG in combination with valproate, LTG Сssmin was 7.8 [5.4; 11.8] mg / l and Cssmax 11.4 [7.3; 15.3] mg/l. In the group that received LTG in combination with drug-inducers of glucuronidation, Cssmin was 2.5 [1.99; 4.32] mg/l, Cssmax 4.73 [2.91; 6.70] mg/l. Statistically significant differences in CDR parameter between groups with LTG monotherapy and duotherapy, both with inducer and with inhibitors, as well as between groups of duotherapy with inductors and with inhibitors were obtained. The results of the study indicate a pronounced pharmacokinetic variability of the LTG. Conducting TDM allows the establishment of individual therapeutic concentrations of LTG in blood plasma and setting a correction vector for antiepileptic therapy.

[Neurourological signs of chronic cerebral vascular diseases].

Disorders of urination, along with motor and cognitive disorders, are characteristic of different forms of chronic cerebral vascular diseases (CCVD). Irritation symptoms are more frequent in subcortical arteriosclerotic encephalopathy (SAE) and multi infarct hypertonic encephalopathy (MIHE). Overactive urine bladder syndrome (OUBS) caused by neurogenic detrusive hyperactivity manifests itself in frequent urination, nocturia and imperative enuresis and thus decreases quality of life and results in disability of patents with CCVD. At the same time, the character of symptoms points indirectly to the localization of lacunar infarction or the extent of severity of leukoareosis. It is the most frequent form of disorders of urination in the first years of disease that significantly aggravates its course and needs timed diagnosis and pharmacological treatment. Competitive antagonists of muscarinic receptors M2, M3 subtypes are the most effective drugs for treatment of OUBS comorbid to CCVD.

[Experience with application of trospium chloride in patients with neurogenic detrusor overactivity].

Overactive bladder (OAB) is observed in such brain diseases as stroke, hypoxic ischemic encephalopathy, Parkinson's disease (PD), multiple sclerosis (MS). Trospium chloride (spasmex) was used in OAB patients with MS (n = 87), stroke (n = 83), encephalopathy (n = 47) and PD (n = 36) in doses from 15 to 45 mg/day in 2 to 36 month courses. The response with minimal side effects was achieved in 94% patients. In addition to basic effects, trospium chloride relieved spastic constipation in patients with stroke, hypersalivation in PD and anal incontinence in MS.

[Prevention of contractures in post-stroke arthropathies]. / Profilaktika kontraktur pri postinsu'ltnykh artropatiiakh.

Arthropathies develop in 15-20% of post-stroke paresis patients. A complex of rehabilitative measures including physical therapy (transcutaneous stimulation analgesia, heating etc.), kinesitherapy and anabolic hormones can prevent contractures if applied at the early rehabilitative stage.

[Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients]. / Opyt primeneniia selektivnykh ingibitorov monoaminoksidazy pri lechenii bol'nykh parkinsonizmom.

MAO B selective inhibitor was given to parkinsonism patients for several months. Positive effect was found in half of the patients irrespective of their age, time of the disease onset and its severity. The drug proved most effective in bradykinesia. Its use is most expedient in combination with L-DOPA-containing drugs which prolong the effect and reduced diurnal shifts in the patients' conditions. Side effects are seldom observed and usually weak.

[Experience with the use of parlodel in the treatment of Parkinson patients]. / Opyt primeneniia parlodela pri lechenii bol'nykh parkinsonizmom.

The dopamine agonist parlodel was given to 42 patients with parkinsonism for several months. The drug proved effective in more than one-third of the patients. Different side-effects were observed in almost half of the patients. Parlodel may be used alone in mild cases but generally it is used as an adjunct to L-DOPA therapy. The optimum dose of parlodel is individual and varies within a wide range.